Global Next-Generation Sequencing on Drug Development Market

Global Next-Generation Sequencing on Drug Development Market

Report Scope:

The scope of this report includes NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS in drug development are given for 2020, 2021, 2022, 2023 and 2028.

This report reviews the NGS technologies and explains why NGS is important in drug development. It then discusses some of the significant research initiatives that impact NGS. The main market-driving forces are also discussed.

This report examines the markets by product type, end user and region. This report provides market data and forecasts for NGS by product type, including instruments, consumables and services for drug development.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific and the Rest of the World.

BCC Research summarizes the main industry acquisitions and strategic alliances from Jan. 2020, through Dec. 2022, including key alliance trends.

Report Includes:

52 data tables and 39 additional tables

An overview of the global markets for next-generation sequencing on drug development

Estimation of market size and analyses of global market trends, with data from 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028

Highlights of the market potential and characterization of next-generation sequencing on drug development market by product, service, end-user type, and region

Examination of the key drivers and constraints that will shape the market for next-generation sequencing on drug development and discussion on the upcoming market opportunities and areas of focus to forecast the market into various segments and subsegments

Coverage of recent advances, emerging technologies, and developments of the industry

Evaluation of key industry acquisitions and strategic alliances and market share analysis of the leading suppliers of the industry

Profiles of the key companies of the industry, including 10x Genomics, Bio-Rad Laboratories Inc., Oxford Nanopore Technologies, Qiagen and Takara Bio Inc.

Companies Mentioned

10X GENOMICS
AGILENT TECHNOLOGIES INC.
BGI (Beijing Genomics Institute)
BIO-RAD LABORATORIES INC.
CD GENOMICS
ILLUMINA INC.
INTEGRATED DNA TECHNOLOGIES INC.
Micronoma
NEW ENGLAND BIOLABS
OXFORD NANOPORE TECHNOLOGIES
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PERKINELMER INC.
PRECISION FOR MEDICINE, FORMERLY APOCELL
PROMEGA CORP.
Psomagen Inc.
QIAGEN
ROCHE HOLDING AG
TAKARA BIO INC.
TECAN GROUP LTD.
THERMO FISHER SCIENTIFIC INC.